JLL Partners Finalizes BioClinica and CoreLab Merger
March 15, 2013
JLL Partners has completed its acquisition of BioClinica (NASDAQ: BIOC) for approximately $123 million ($7.25 per share). The firm concurrently acquired CoreLab Partners, an Ampersand Capital Partners portfolio company, and merged the two entities under the BioClinica name. The combined company provides imaging core lab services, cardiovascular safety monitoring and eClinical trial management solutions to the global healthcare industry. Ampersand provided an equity commitment alongside JLL to finance the BioClinica acquisition, and will be a significant investor in the combined company.